What is this all about? On January 2, Anavex announced results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX ® 2-73 in pediatric patients with Rett syndrome. The study failed to show statistical significance towards its primary endpoints, causing shares of Anavex Life Sciences Corp. stock to drop approximately 35%. Who is eligible? Anyone who purchased Anavex Life Sciences Corp. stock between February 1, 2022 and January 1, 2024, and has lost money may be eligible, whether or not they have sold their investment.